NEWS
New Scientific Publication
We are proud to share the publication of a new scientific article: “Ozone-driven NRF2 activation boosts osteoblast activity: Implications for skeletal diseases,” published in Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease.
The research, conducted by the University of Pavia in collaboration with Fondazione IRCCS Policlinico San Matteo, explores how medical ozone can stimulate the activity of osteoblasts, the cells responsible for building new bone tissue. The study shows that a controlled, low-concentration ozone treatment activates a natural cellular defense mechanism (known as NRF2), which in turn boosts bone-forming activity and helps restore healthy cell function, even in cells carrying the genetic alteration responsible for a bone fragility disease. These findings open promising perspectives for the use of medical ozone in supporting bone health and fracture healing.
At Paolo Gobbi Frattini S.r.l., medical ozone has been part of our identity for decades, and seeing rigorous scientific research continue to uncover new mechanisms behind its benefits is exactly the kind of progress we are proud to support. As a company, we contributed to funding this project, and we are truly proud of the results it has achieved.
We want to warmly congratulate the University of Pavia and, in particular, Alessandra Sala and Roberta Besio, along with all the researchers involved, for this valuable contribution to the scientific community. Supporting research like this is at the heart of what we do, and we look forward to continuing to support the scientific community in exploring the full potential of medical ozone.
We are proud to announce the official launch of our 13th automated production line
Integrating next-generation applications tailored for 𝐈.𝐕. 𝐞𝐦𝐩𝐭𝐲 𝐛𝐚𝐠 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧, this manufacturing system marks a major milestone in our drive toward industry leadership and process optimization.
Through this investment, we further elevate our standards of operational efficiency and precision to promptly address the evolving demands of the pharmaceutical and healthcare sectors.
A special thank you to our entire team and partners whose expertise and dedication made this achievement possible.
Stem cells, Paolo Gobbi Frattini S.r.l. Unipersonale patents
We are proud to announce that our commitment to scientific research has recently been recognized by the press.
The weekly newspaper Centro Valle has published an article about the collaboration between Paolo Gobbi Frattini S.r.l. and the University of Pavia, focusing on our joint activities in the field of stem cell research.
The article can also be found on the Prima La Valtellina website.
ADIPOCHOICE®: International Patent Application Published
We are pleased to announce that our patent application for ADIPOCHOICE®, an innovative method for preparing human or animal adipose tissue grafts intended for autotransplantation, has been published in both the EU and US.
This important milestone is the result of the work carried out by the R&D Life Science department of Paolo Gobbi Frattini S.r.l., which has developed a cutting-edge solution to improve the efficacy and safety of adipose tissue grafts.
The transfer of adipose tissue from areas rich in fat, such as the abdomen or thighs, to desired areas like the breasts or glutes, is a well-established procedure in reconstructive and aesthetic surgery. The use of autologous adipose tissue significantly reduces the risk of rejection and allows for the avoidance of artificial prostheses.
Our innovation introduces a closed-circuit system during the preparation phase, ensuring a controlled and sterile environment. Furthermore, the process incorporates a treatment with an adjuvant during graft preparation, offering two main advantages:
- Enhanced efficacy and safety: the adjuvant treatment enhances the functionality of the graft while ensuring optimal preparation conditions that contribute to a safer and more reliable outcome in autologous adipose tissue grafting.
- Cellular stimulation: the treatment promotes the antioxidant response of the cells, activating adipogenesis and stimulating the regenerative and stem cells present in the graft. This increases cellular vitality and improves the chances of successful grafting.
Thanks to this method, ADIPOCHOICE® effectively addresses common challenges associated with adipose tissue grafts, such as infections, necrosis, graft resorption, calcifications, and scar formation. By enhancing the activity of regenerative cells, and ensuring a sterile environment through the closed-circuit, it represents a significant advancement in the field of regenerative medicine and medical devices.
Introducing
Accelerating Innovation in Stem Cells
The R&D Life Science department of Paolo Gobbi Frattini S.r.l. Unipersonale, in collaboration with the Department of Molecular Medicine at the University of Pavia announces the project of research and development of a new method, RIGENERA®, to extract Hematopoietic Stem Cells (HSCs) obtainable from blood samples of various types (peripheral, cord or marrow blood), with different yield percentages. The aim is to obtain a better yield of HSCs in terms of quality and quantity for autologous transplantation in patients subject to hematological malignancies, other hematological diseases, and solid tumors.
To this day, many diseases still exist whose therapeutic strategy only focuses on reducing symptoms rather than achieving permanent resolution. For many of these conditions, the hope for a cure lies in regenerative medicine, which aims to protect and repair damaged organs or tissues through the application of cell therapies involving stem cells, including Hematopoietic Stem Cells (HSCs). HSCs can be obtained, with different yield percentages, from blood samples of various types (peripheral, cord or marrow blood).
Different techniques exist to separate blood cells to obtain a specific target population, such as HSCs. However, multiple centrifuge phases are required, which may damage the cells and affect the extraction yield.
This is where the collaboration between the University of Pavia and Paolo Gobbi Frattini S.r.l. was born, with the objective of developing a method, RIGENERA®, for extracting HSCs from blood samples with a better yield in terms of quality and quantity.
Specifically, the collaboration aims to extract HSCs using a new biocompatible liquid, developed by Paolo Gobbi Frattini S.r.l. Unipersonale, composed of high molecular weight dextran polymers, which will minimize the mechanical stress to which the cells are subjected with the traditional methods.
Together with an alternative separation method of HSCs, the potential and the beneficial effects of an adjuvant will be evaluated on blood samples, to further increase vitality and number of cells, as demonstrated in literature. The beneficial effects of the adjuvant are based on its capacity to induce a low-density oxidative stress, stimulating cytoprotective pathways through the activation of the genes involved in the antioxidant response (ARE), which protect cells from endogenous and exogenous insults.
It is our wish that RIGENERA® may be used in the future as the gold standard for therapeutic transplants, leading to advancements in the field of regenerative medicine.
We are pleased to welcome you to our upcoming events!
This is a unique opportunity to meet in person, discuss your needs, and explore the latest industry innovations.
We look forward to sharing ideas and projects with you!
